Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.

doi:10.1016/j.jneuroim.2006.10.011

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.

Journal of neuroimmunology - 1 Jan 2007

Weinstock-Guttman Bianca, Tamaño-Blanco Miriam, Bhasi Kavitha, Zivadinov Robert, Ramanathan Murali

Abstract excerpt

The myxovirus resistance A (MXA) mRNA has been extensively investigated for assessing the biologic responses of multiple sclerosis (MS) patients to interferon-beta (IFN-beta) therapy. The objective of this study was to evaluate the associations between two MXA promoter region single nucleotide polymorphisms (rs2071430 and rs17000900) and the gene expression responses, clinical and MRI phenotypes in IFN-beta...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain

Share to Disability Evaluation

Share to GTP-Binding Proteins

Share to Immunologic Factors

Share to Interferon-beta

Share to Magnetic Resonance Imaging

Share to Multiple Sclerosis, Relapsing-Remitting

Share to Myxovirus Resistance Proteins

Source

Open in PubMed

Identifiers

PMID: 17126411
DOI: 10.1016/j.jneuroim.2006.10.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.PMID 17126411Read ↗

Myxovirus resistance protein A (MxA) polymorphism is associated with IFNβ response in Iranian multiple sclerosis patients.Semantic proximity Read ↗

Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes.Semantic proximity Read ↗

Single nucleotide polymorphisms and functional analysis of MxA promoter region in multiple sclerosis.Semantic proximity Read ↗

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.Semantic proximity Read ↗

Association study of promoter polymorphisms of interferon alpha and beta receptor subunit 1 (IFNAR1) gene and therapeutic response to interferon-beta in patients with multiple sclerosis.Semantic proximity Read ↗

Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.Semantic proximity Read ↗

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.Semantic proximity Read ↗

Analysis of Association Between Genetic Heterogeneity of Interferon Beta Receptor Promoter and Therapeutic Response to Interferon-beta in a Patient with Multiple SclerosisSemantic proximity Read ↗

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1Semantic proximity Read ↗

IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.Semantic proximity Read ↗

Search for Specific Biomarkers of IFNβ Bioactivity in Patients with Multiple SclerosisSemantic proximity Read ↗

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.